By Topic
PolyNovo (ASX: PNV): Our Bottoming Thesis Confirmed by a Breakout Move
PolyNovo (ASX: PNV) is an advanced wound care company whose NovoSorb platform drives strong U.S.-led growth. After the March weakness from leadership changes, improving revenues and a technical breakout above the trend signal a potential bottom and renewed bullish momentum.
AnteoTech (ASX: ADO) Rockets Higher as Battery Tech Breakthrough Ignites Massive Share Price Surge
AnteoTech (ASX: ADO) surged over 46% after independent validation of its Ultranode™ 95 silicon anode technology in commercial battery cells, boosting energy density. The breakthrough reignited investor interest in the speculative micro-cap amid hopes of future battery partnerships.
Clarity Pharmaceuticals (ASX: CU6) Shares Edge Higher After Investors React to Recent Price Swing
Clarity Pharmaceuticals (ASX: CU6) has seen renewed share price volatility as investors react to clinical updates and broader ASX healthcare swings. Despite pullbacks, interest in its radiopharmaceutical pipeline remains, especially SAR-bisPSMA. The company remains unprofitable, with valuation driven by trial progress and long-term oncology potential rather than current earnings.
Is Ionic Rare Earths (ASX: IXR) Building a New Medium Term Bullish Trend?
Ionic Rare Earths is an Australia-based company developing a vertically integrated rare earth supply chain across mining, refining, and recycling, anchored by its Makuutu project in Uganda and UK processing operations, targeting clean energy, manufacturing, and defence markets.
Has Galan Lithium (ASX: GLN) Built a Durable Base for Its Next Leg Higher?
Galan Lithium (ASX: GLN) is an Australian developer focused on high-grade lithium brine projects in Argentina, led by Hombre Muerto West. It is advancing toward production, supported by strong lithium prices, funding, and expansion, though dilution and execution risks remain.
Imugene (ASX: IMU) Roars Back to Life as Explosive Share Price Rebound Sparks Fresh Speculative Buzz
Imugene (ASX: IMU) surged over 35% after early Azer-cel trial results showed strong response rates in blood cancer patients, reigniting biotech speculation. Despite the rally, the stock remains highly volatile and pre-revenue, with future moves dependent on clinical progress, funding needs, and upcoming ASCO updates.
...